Medicine Details
Brand name – Olumiant
Generic name – Baricitinib
Manufacturer – Eli Lilly and Co.
Salt composition – Baricitinib
Disease indication – Rheumatoid arthritis
Storage – Store at 20-25°C (68-77°F)
Dosage form – oral
Strength – 2mg, 4mg
Packaging – bottle of 30 tablets
Gender – Unisex
Indication – used in the treatment of adult patients with moderately to severely active Rheumatoid Arthritis.
Description
Olumiant (baricitinib) is used for the treatment of adult patients with active rheumatoid arthritis, who already have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Baricitinib blocks the activity of certain enzymes that are involved in activating inflammation in the body. Olumiant 2 mg tablet is light pink, debossed with “Lilly” on one side and “2” on the other. Olumiant 4 mg tablet is light pink, debossed with “Lilly” on one side and “4” on the other.
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family. They play a crucial role in the proinflammatory pathway signalling that is frequently over-activated in rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib works to disrupt the activation of downstream signalling molecules and proinflammatory mediators.
Pharmacodynamics
Baricitinib inhibition of IL-6 induced STAT3 phosphorylation
Baricitinib administration resulted in a dose-dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed approximately 1 hour after dosing, which returned to near baseline by 24 hours. Similar levels of inhibition were seen using either IL-6 or TPO as the stimulus.
Immunoglobulins
Mean serum IgG, IgM, and IgA values decreased by 12 weeks after starting treatment with Olumiant, and remained stable through at least 52 weeks. For most patients, changes in immunoglobulins occurred within the normal reference range.
C-reactive protein
In patients with rheumatoid arthritis, decreases in serum C-reactive protein (CRP) were observed as early as one week after starting treatment with Olumiant and were maintained throughout dosing.
Cardiac Electrophysiology
At a dose 10 times the maximum recommended dose, baricitinib does not prolong the QT interval to any clinically relevant extent.
Ingredients
The active ingredient in Olumiant is Baricitinib. Other ingredients are croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, iron oxide red, lecithin, macrogol 3350, polyvinyl alcohol, purified talc and titanium dioxide.
Usage Of Olumiant (Baricitinib)
Olumiant (baricitinib) is used for the treatment of adult patients with active rheumatoid arthritis, who already have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Side Effects
Common Side Effects
- Common cold
- Sinus
- Shingles
- Stomach ache
- Weight loss
- Feeling tiredness
- Sore throat
- Skin rash
- Muscle pain
- Joint pain
- Fever and chills
Serious Side Effects
- Shortness of breath
- Difficulty in breathing
- Swelling of the lips and tongue
- Increased urination
- Pain or burning when you urinate
- Chest pain
- Rapid breathing
- Coughing up pink or red mucus
- Night sweats
- Swelling or redness in an arm or leg
- Change in bowel habits
- Skin sores
- Unusual sweating
Dosage
Missed Dose
Skip the missed dose if it is already time for the next dose. Do not double the dose to catch up.
Overdose
Seek emergency medical help in case of overdose.
Warning And Precautions
Before consuming Olumiant (baricitinib), make sure to tell your healthcare provider if you:
- Already have an infection that doesn’t go away easily or are being treated for an infection.
- Have TB or have been in close contact with someone with TB.
- Have or have had hepatitis B or C
- Have cancer
- Have blood clots in the veins of your legs or lungs.
- Have kidney or liver problems
- Have diabetes
- Have lung disease
- Have HIV
- Have a weak immune system
- Have any stomach-area pain
- Have been diagnosed with inflammation in the large intestine or ulcers in your stomach or intestines.
- Have recently received a vaccine
- Are planning to receive a vaccine
- Are pregnant
- Are planning to become pregnant
- Are breastfeeding or planning to breastfeed.
- Are taking other medicines, including prescribed supplements.
- Are under age 18 (because it is not known if Olumiant is safe and effective in children).
It is not known if Olumiant is safe and effective in children (below age 18).
It is recommended to not consume Olumiant (baricitinib) during breastfeeding.
